Aravax is a clinical stage biotechnology company focused on developing innovative treatments for food allergies. The company leverages proprietary technology to precisely reset the immune system, enabling it to tolerate allergens without triggering allergic reactions during treatment. Aravax's lead product, PVX108, targets peanut allergies and has successfully completed Phase 1 clinical trials. Currently, Phase 2 trials are underway, recruiting peanut allergic adolescents and children in clinics across Australia and the United States. Founded in May 2015, Aravax emerged from intellectual property developed by Alfred Health and Monash University, with initial investment from the Medical Research Commercialisation Fund (MCRF), managed by Brandon Capital Partners. In January 2024, Aravax closed a Series B funding round, attracting new investors including Novartis Venture Fund, Tenmile, Breakthrough Victoria, Uniseed, and UniSuper. This funding supports the ongoing Phase 2 development of PVX108 and the expansion of Aravax's product pipeline. Aravax primarily serves patients with food allergies, operating within the biotechnology and healthcare markets. The company's business model revolves around the development and commercialization of its proprietary treatments, generating revenue through clinical trials and eventual product sales.

Keywords: biotechnology, food allergies, immune system, PVX108, clinical trials, peanut allergy, proprietary technology, healthcare, Series B funding, commercialization.